knowledge -WSS

knowledge

author：fashion 2025-09-30 19:03:28 - browse：89615

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： DeSantis can now import cheaper drugs. But will Biden get credit?

hotspot

WSS

Heart disease and mental health: A look at cardiac psychology

Designating disabled people as health disparity population is crucial

Heart disease and mental health: A look at cardiac psychology

Readout LOUD podcast: live from JPM 2024

The nurse manager staffing crisis is hurting patients

Midwives could help bridge maternal health disparities in the U.S.

entertainment

knowledge

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Heart disease and mental health: A look at cardiac psychology

Medical leaders decry Supreme Court decision on affirmative action

The nurse manager staffing crisis is hurting patients

Anesthesiologist group: stop taking Ozempic before surgery

New menopause drug shows promise in relief for hot flashes

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Wildfire smoke exposes gaps in outdoor worker protections

Grad students accuse University of California of wage theft

hotspot

DeSantis can now import cheaper drugs. But will Biden get credit?

Doulas covered by Medicaid under New York's new plan

Fed up with FDA, ALS advocates consider a take

The nurse manager staffing crisis is hurting patients

Fauci’s Covid grilling leads GOP to weigh foreign research rules

HHS names first

entertainment

Wikipedia

hotspot

focus